Stryker Corporation (SYK) is a Healthcare stock trading at $327.19 (as of 2026-07-09), with a market capitalization of $125.43B and a trailing P/E of 37.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Stryker makes medical technology, selling orthopedic and spine implants (for hip and knee joint replacements, trauma and extremities surgeries, and spinal treatments) and surgical equipment and navigation systems, and it makes money by selling these products to support surgeries.
Stryker’s profit engine is tied to surgical demand, because its offerings include implants used in hip and knee replacements, trauma and extremities surgeries, and spinal injury, deformity, and degenerative therapies, plus surgical equipment and navigation systems used in those procedures.
| MedSurg+Neuro | $3.9B |
| Ortho+Spine | $2.3B |
Business quality (Mixed): Stryker has a clear two-segment product model across implants and surgical technology, but the dataset provided here does not include operating KPIs to track day to day performance beyond reported results.
Valuation: At 39× earnings, SYK trades 19% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $327.19 |
| Market Cap | $125.43B |
| P/E Ratio | 37.6 |
| EV / EBITDA | 20.8 |
| Price / Book | 5.46 |
| Price / Sales | 4.96 |
| FCF Yield | 3.6% |
| DCF Value (model) | $89.38 |
| DCF Upside vs Price | -72.7% |
| Revenue (TTM) | $25.12B |
| Net Margin | 12.9% |
| Revenue Growth (YoY) | 2.6% |
| EPS Growth (YoY) | 14.0% |
| FCF Growth (YoY) | 226.8% |
| Altman Z-Score | 4.59 (safe) |
| Piotroski F-Score | 4/9 (moderate) |
| Stock P/E | 37.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Medical Equipment) | 29.8 |
| vs Sector | 73.4% |
| vs Industry | 26.0% |
| Insider Sells (12mo) | 45 |
| Top Institutional Holder | VANGUARD GROUP INC ($11.92B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Kevin A. Lobo |
| Employees | 53,000 |
| Country | US |
| IPO Date | 1980-03-17 |
Data as of 2026-07-09.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.